The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis;Účinnost lenalidomidu u vzácných krevních chorob: U histiocytózy z Langerhansových buněk, multicentrické Castlemanovy choroby, POEMS syndromu, Erdheimovy-Chesterovy choroby a angiomatózy. Popis pří padů a přehled literatury

Vnitrni Lekarstvi

Volumn 58, Issue 11, 2012, Pages 856-866

  Adam, Z ^a   Pour, L ^a   Krejci M ^a   Zahradova L ^a   Szturz, P ^a   Koukalova R ^b   Rehak Z ^b   Nebesky T ^c   Hajek R ^a   Kral Z ^a   Mayer, J ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b Centrum PET Masarykova Onkologickeho Ustavu Brno   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Anakinra; Angiomatosis; Castleman disease; Cladribin; Erdheim Chester disease; Langerhans cell histiocytosis; Lenalidomide; Poems syndrome; Thalidomide

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; LENALIDOMIDE; MELPHALAN; OCTREOTIDE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERDHEIM CHESTER DISEASE; HEMANGIOMATOSIS; HEMATOLOGIC DISEASE; HUMAN; LANGERHANS CELL HISTIOCYTOSIS; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELOMA; NEUROPATHY; POEMS SYNDROME; RARE DISEASE; REMISSION; TREATMENT RESPONSE;

AGED; ERDHEIM-CHESTER DISEASE; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; MALE; MIDDLE AGED; POEMS SYNDROME; THALIDOMIDE;

EID: 84870955401     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Sčudla V, Pika T, Budíková M et al. Příspěvek k hodnocení vztahů mezi angiogenními cytokiny, vybranými biologickými parametry a prognostickými faktory u mnohočetného myelomu. Čas Lék Česk 2006; 145: 929-935.
2. Sčudla V, Bačovský J, Indrák K et al. Výsledky léčby a změny v prognóze pacientů s mnohočetným myelomem v oblasti centrální a severní Moravy v posledních 40 letech. Vnitř Lék 2002; 48: 707-717.
3. Sčudla V. Anémie chronických chorob. Standardy pro diagnostiku a léčbu. Vnitř Lék 2002; 48: 422-426.
4. Minařík J, Pika T, Baovský J et al. Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance. Scientific World Journal 2012; 2012: 356128. Epub 2012 Apr 26.
5. Minařík J, Sčudla V, Bačovský J et al. Comparison of imaging methods in POEMS syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156: 52-57.
6. Sčudla V, Minařík J, Pika T. Light chain deposition disease. Vnitř Lék 2012; 58: 38-43.
7. Sčudla V, Petrová P, Minařík J et al. Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma. Neoplasma 2011; 58: 499-506.
8. Minařík J, Sčudla V, Tichý T et al. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement. Leuk Lymphoma 2012; 53: 330-331.
9. Sčudla V, Herman M, Minařík J et al. Přínos celotělové magnetické resonance pro diagnostiku monoklonální gammopatie nejistého významu a mnohočetného myelomu. VnitřLék 2011; 57: 52-60.
10. Myslivrček M, Bačovský J, Sčudla V et al. 18F-FDG PET/CT a 99mTc-MIBI scintigrafie při hodnocení pacientů s mnohočetným myelomem a monoklonální gamapatií nejistého významu. Srovnání metod. Klin Onkol 2010; 23: 325-331.
11. Bačovský J, Mysliveček M, Sčudla V et al. Tc-99m MIBI scintigraphy in multiple myeloma: prognostic value of different Tc-99m MIBI uptake patterns. Clin Nucl Med 2010; 35: 667-670.
12. Sčudla V, Pika T, Budíková M et al. The relationship between some soluble osteogenic markers, angiogenic cytokines/other biological parameters and the stages of multiple myeloma evaluated according to the Durie-Salmon and International Prognostic Index stratification systems. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153: 275-282.
13. Minařík J, Sčudla V, Ordeltová M et al. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. Eur J Haematol 2009; 83: 528-534.
14. Krejci M, Scudla V, Tothova E, et al. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse. Clin Lymphoma Myeloma. 2009; 9 (6): 436-442.
15. Beličková M, Čermák J, Dostá lová Merkerová M et al. Changes Associated With Lenalidomide Treatment in the Gene Expression Profiles of Patients With Del(5q). Clin Lymphoma Myeloma Leuk 2012; 12: 375-383.
16. Giagounidis AA, Kulasekararaj A, Germing U et al. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia 2012; 26: 855-858.
17. Segler A, Tsimberidou AM. Lenalidomide in solid tumors. Cancer Chemother Pharmacol 2012; 69: 1393-1406.
18. Gasent Blesa JM, Godoy MP, Esparcia MF et al. Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report. Case Rep Oncol 2012; 5: 181-186.
19. Holánek M, Hájek R. Použití lenalidomidu pro léčbu mnohočetného myelomu. Klin Onkol 2010; 23: 67-72.
20. Machálková K, Maisnar V. Léčba mnohočetného myelomu lenalidomidem. Klin Onkol 2009; 22: 117-120.
21. Novotová E, Neuwirtová R, Jonášová A et al. Lenalidomid (Revlimid) v léčbě mnohoč etného myelomu - první zkušenosti v České republice. Čas Lék Česk 2008; 147: 623-626.
22. Kessler P. Profylaxe a léčbě trombembolismu v onkologii. Vnitř Lék 2009; 55: 219-222.
23. Radocha J, Maisnar V. Nízké dávky thalidomidu u refrakterního a relaxujícího myelomu. Vnitř Lék 2007; 53: 129-134.
24. Zbořil V. Idiopatické střevní záněty - současné léčebné možnosti. Vnitř Lék 2004; 50: (Suppl. 1): S94-S97.
25. Foldyna D, Kamelander J, Krejčí M et al. Žádoucí a nežádoucí účinky thalidomidu u pacientů s mnohočetným myelomem. Vnitř Lék 2003; 49: 859-868.
26. Habermann TM. New developments in the management of diffuse large B-cell lymphoma. Hematology 2012; 17: (Suppl. 1): S93-S97.
27. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544-1552.
28. Witzig TE, Wiernik PH, Moore T et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 5404-5409.
29. Dueck G, Chua N, Prasad A et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010; 116: 4541-4548.
30. Hernandez Ilizaliturri FJ, Deeb G, Zinzani PL et al. Higher response to lenalidomide in relapsed/refractory difusse large B-cell lymphoma in non germinal center B-cell lie then in germinal center B-cell like phenotype. Cancer 2011; 117: 5058-5066.
31. Zinzani PL, Pellegrini C, Gandolfi L et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011; 11: 462-466.
32. Czuczman MS, Vose JM, Witzig TE et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol 2011; 154: 477-481.
33. Witzig TE, Vose JM, Zinzani PL et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
34. Tempescul A, Ianotto JC, Eveillard JR et al. Chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation. Ann Hematol 2011; 90: 971-973.
35. Zaja F, De Luca S, Vitolo U et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416-422.
36. Habermann TM, Lossos IS, Justice G et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145: 344-349.
37. Musuraca G, Fattori PP, Ceccolini M et al. Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor. Am J Hematol 2011; 86: 79-80.
38. Ivanov V, Tabouret E, Chuto G et al. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2010; 51: 1758-1760.
39. Böll B, Borchmann P, Topp MS et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010; 148: 480-482.
40. Cox MC, Mannino G, Lionetto L et al. Lenalidomide for aggressive B-cell lymphoma involving the central nervous system. Am J Hematol 2011; 86: 957-958.
41. Chanan-Khan AA, Chitta K, Ersing N et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and anti-tumour response. Br J Haematol 2011; 155: 457-467.
42. Andritsos LA, Johnson AJ, Lozanski G et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 2519-2525.
43. Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343-5349. (Pubitemid 46623164)
44. Ferrajoli A, Lee BN, Schiene EJ et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291-5297.
45. Srinivasan S, Schiffer CA. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. Leuk Res 2009; 33: 561-564.
46. Sher T, Miller KC, Lawrence D et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010; 51: 85-58.
47. Badoux XC, Keating MJ, Wen S et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011; 118: 3489-3498.
48. Chen CI, Bergsagel PL, Paul H et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 1175-1181.
49. Wendtner CM. Lenalidomide in CLL what is the optimal dose? Clin Adv Hematol Oncol 2011; 9: 220-224.
50. Giannopoulos K, Mertens D, Stilgenbauer S. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. Expert Opin Pharmacother 2011; 12: 2857-2864.
51. Pinto A, Corazzelli G, De Filippi R. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2012; 118: 1738-1739.
52. Arumainathan A, Kalakonda N, Pettitt AR. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. Eur J Haematol 2011; 87: 372-375.
53. Gentile M, Recchia AG, Vigna E et al. Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs 2011; 20: 273-286.
54. Awan FT, Johnson AJ, Lapalombella R et al. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51: 27-38.
55. Sčudla V, Roček V, Dušek J et al. Multifokální eozinofilní granulom v dospělosti. Vnitř Lék 1987; 33: 1078-1086.
56. Adam Z, Řehák Z, Koukalová R et al. Lenalidomid indukoval léčebnou odpověd' u pacienta s agresivní multisystémovou formou histiocytózy z Langerhansových buněk (LCH), rezistentní ke 2-chlorodeoxyadenosinu a časně relabující po vysokodávkované chemoterapii BEAM s autologní transplantací kmenových hemopoetických buněk. Vnitř Lék 2012; 58: 62-71.
57. Szturz P, Adam Z, Řehák Z et al. Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncol 2012; 51: 412-415.
58. Adam Z, Šprláková A, Řehák Z et al. Parciální regrese ložisek Erdheimovy-Chesterovy nemoci v CNS po léčbě 2-chlorodeoxadenosinem a jejich kompletní vymizení při léčbě lenalidomidem. Popis případu a přehled literá rních údajů. Klinická onkologie 2011; 24: 367-382.
59. Adam Z, Matýšková M, Tomíška M et al. Šestileté sledování pacienta s mnohočetnou angiomatózou postihující skelet, břiš ní i hrudní dutinu a stěnu trávicí trubice. Hodnocení vlivu zoledronatu, interferonu alfa, thalidomidu a lenalidomidu na aktivitu této nemoci. Klinická Onkologie 2012; 25: 47-62.
60. Bowcock SJ, Patrick HE. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias? Br J Haematol 2009; 146: 220-222.
61. Sumrall A, Fredericks R, Berthold A et al. Lenalidomide stops progression of multifocal epithetoid hemangioendothelioma including intracranial disease. J Neurooncol 2010; 97: 275-277.
62. Szturz P, Moulis M, Adam Z et al. Castleman disease. Klin Onkol 2011; 24: 424-434.
63. Ramasamy K, Gandhi S, Tenant-Flowers M et al. Rituximab and thalidomide combination therapy for Castleman disease. Br J Haematol 2012; 158: 421-423.
64. Wang X, Ye S, Xiong C et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease. Jpn J Clin Oncol 2011; 41: 1221-1224.
65. Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 591-601.
66. Kim SY, Lee SA, Ryoo HM et al. Thalidomide for POEMS syndrome. Ann Hematol 2006; 85: 545-546.
67. Starkey CR, Joste NE, Lee FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 2006; 81: 303-304.
68. Menegato MA, Canelles MF, Tonutti E et al. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. Clin Nephrol 2004; 61: 352-356. (Pubitemid 38579022)
69. Jung CP, Emmerich B, Goebel FD et al. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 2004; 75: 176-177. (Pubitemid 38263829)
70. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003; 73: 48-53. (Pubitemid 36504579)
71. Stary G, Kohrgruber N, Herneth AM et al. Complete regression of HIV-associated multi-centric Castleman disease treated with rituximab and thalidomide. AIDS 2008; 22: 1232-1234.
72. Zhao X, Shi R, Jin X et al. Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases. J Am Acad Dermatol 2011; 65: 430-432.
73. Vannata B, Laurenti L, Chiusolo P et al. Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. Am J Hematol 2012; 87: 641-642.
74. Briani C, Manara R, Lessi F et al. Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy. Am J Hematol 2012; 87: 539-541.
75. Tomás JF, Giraldo P, Lecumberri R et al. POEMS syndrome with severe neurological damage clinically recovered with lenalidomide. Haematologica 2012; 97: 320-322.
76. Suyani E, Yaǧci M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol 2011; 126: 199-201.
77. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Casdeman's disease. Am J Hematol. 2012; 87(11): 997-1002.
78. Sethi S, Tageja N, Arabi H et al. Lenalidomide therapy in a rare case of POEMS syndrome with kappa restriction. South Med J 2009; 102: 1092-1093.
79. Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007; 110: 1075-1076. (Pubitemid 47267453)
80. Szturz P, Adam Z, Chovancová J et al. Lenalidomide: a new treatment option for Castleman disease. Leuk Lymphoma 2011; 53: 2089-2091.